| Name | Title | Contact Details |
|---|
CHF Solutions, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioMedical Strategies is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Lexington, MA, iSpecimen offers an online marketplace for the purchase of human biospecimens, providing researchers with the specimens they need from the patients they want. The iSpecimen Marketplace connects healthcare organizations that have access to patients and specimens with the scientists who need them for their research and development projects. Proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. And ultimately, healthcare advances for all.
Duramed Mobility Florida is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.